Physician profile
Peter Mariani
NPI 1679520514
$1,813.92
in general payments reported to CMS, 2019-2025
14 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $346 · 2023: $251 · 2024: $656 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $594.05 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $260.50 | 2022-2025 | Fasenra, Airsupra |
| Kestra Medical Technology Services, INC. | $191.45 | 2022-2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.69 | 2023-2025 | Jascayd, Ofev |
| Boston Scientific Corporation | $128.39 | 2024-2025 | Watchman Access System |
| Pfizer INC. | $102.95 | 2022-2025 | |
| Novo Nordisk INC | $98.97 | 2022-2025 | Wegovy |
| Heartflow, INC. | $69.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $57.79 | 2022-2023 | Xarelto |
| Amgen INC. | $46.36 | 2022-2024 | Tezspire |
| Lilly USA, LLC | $32.41 | 2023-2025 | Mounjaro, Zepbound |
| Aimmune Therapeutics, INC. | $29.88 | 2025 | Zenpep |
| Dexcom, INC. | $22.75 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $20.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mariani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.